Terug
Dagbereik
€ 232,24
€ 236,00
52-Weeksbereik
€ 141,50
€ 251,71
Volume
5.184.429
50D / 200D Gem.
€ 234,14
/
€ 194,58
Vorige Slotkoers
€ 235,42
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 21,2 | 0,3 |
| P/B | 7,0 | 2,9 |
| ROE % | 35,0 | 3,7 |
| Net Margin % | 28,5 | 3,8 |
| Rev Growth 5Y % | 4,6 | 10,0 |
| D/E | 0,6 | 0,2 |
Koersdoel Analisten
Hold
€ 228,73
-2.8%
Low: € 190,00
High: € 265,00
Forward K/W
20,4
Forward WPA
€ 11,56
WPA Groei (sch.)
+0,0%
Omzet Sch.
100 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 16,71
€ 16,10 – € 17,19
|
130 B | 2 |
| FY2029 |
€ 15,06
€ 14,51 – € 15,49
|
120 B | 2 |
| FY2028 |
€ 13,73
€ 10,81 – € 16,03
|
110 B | 5 |
Insider Trading Activity
Buy ratio (90d)
0.0%
13 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 |
Decker Robert J
VP Corporate Controller
|
sell | 4.075 | € 247,87 | € 1.010.070 |
| Feb 27, 2026 |
Decker Robert J
VP Corporate Controller
|
other | 8.150 | € 115,67 | — |
| Feb 20, 2026 |
Schmid Timothy
EVP, WW Chair, MedTech
|
sell | 1.322 | € 245,66 | € 324.763 |
| Feb 9, 2026 |
Broadhurst Vanessa
EVP, Global Corp Affairs
|
grant | 8.594 | — | — |
| Feb 9, 2026 |
Decker Robert J
VP Corporate Controller
|
grant | 2.741 | — | — |
| Feb 6, 2026 |
Mulholland Kristen
EVP, Chief HR Officer
|
other | 14.585 | € 101,87 | € 1.946.404 |
| Nov 26, 2025 |
MORIKIS JOHN G
Director
|
buy | 1.250 | € 206,15 | € 257.688 |
| Sep 9, 2025 |
Woods Eugene A.
Director
|
grant | 211 | € 178,07 | € 37.573 |
| Jul 17, 2025 |
REED JOHN C
EVP, Innovative Medicine, R&D
|
sell | 19.137 | € 163,55 | € 3.129.830 |
| Jun 10, 2025 |
HEWSON MARILLYN A
Director
|
grant | 322 | € 155,23 | € 49.984 |
| Apr 24, 2025 |
WEINBERGER MARK A
Director
|
grant | 1.316 | — | — |
| Apr 24, 2025 |
McClellan Mark B.
Director
|
grant | 1.316 | — | — |
| Apr 24, 2025 |
Woods Eugene A.
Director
|
grant | 1.316 | — | — |
Belangrijkste Punten
Revenue grew 4,58% annually over 5 years — modest growth
Earnings grew 90,56% over the past year
ROE of 35,03% indicates high profitability
Net margin of 28,46% shows strong profitability
Generating 19,70B in free cash flow
PEG of 0,21 suggests growth is underpriced
Groei
Revenue Growth (5Y)
4,58%
Revenue (1Y)6,05%
Earnings (1Y)90,56%
FCF Growth (3Y)3,90%
Kwaliteit
Return on Equity
35,03%
ROIC14,83%
Net Margin28,46%
Op. Margin27,17%
Veiligheid
Debt / Equity
0,59
Current Ratio1,03
Interest Coverage26,36
Waardering
P/E Ratio
21,15
P/B Ratio6,95
EV/EBITDA23,25
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6,05% | Revenue Growth (3Y) | 5,17% |
| Earnings Growth (1Y) | 90,56% | Earnings Growth (3Y) | -12,68% |
| Revenue Growth (5Y) | 4,58% | Earnings Growth (5Y) | 6,45% |
| Profitability | |||
| Revenue (TTM) | 94,19B | Net Income (TTM) | 26,80B |
| ROE | 35,03% | ROA | 13,46% |
| Gross Margin | 72,78% | Operating Margin | 27,17% |
| Net Margin | 28,46% | Free Cash Flow (TTM) | 19,70B |
| ROIC | 14,83% | FCF Growth (3Y) | 3,90% |
| Safety | |||
| Debt / Equity | 0,59 | Current Ratio | 1,03 |
| Interest Coverage | 26,36 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 21,15 | P/B Ratio | 6,95 |
| P/S Ratio | 6,02 | PEG Ratio | 0,21 |
| EV/EBITDA | 23,25 | Dividend Yield | 0,02% |
| Market Cap | 566,98B | Enterprise Value | 595,20B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 94,19B | 88,82B | 85,16B | 79,99B | 78,74B |
| Net Income | 26,80B | 14,07B | 35,15B | 17,94B | 20,88B |
| EPS (Diluted) | 11,03 | 5,79 | 13,72 | 6,73 | 7,81 |
| Gross Profit | 68,56B | 61,35B | 58,61B | 55,39B | 55,34B |
| Operating Income | 25,60B | 22,15B | 23,41B | 21,01B | 20,94B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 199,21B | 180,10B | 167,56B | 187,38B | 182,02B |
| Total Liabilities | 117,67B | 108,61B | 98,78B | 110,57B | 108,00B |
| Shareholders' Equity | 81,54B | 71,49B | 68,77B | 76,80B | 74,02B |
| Total Debt | 47,93B | 36,63B | 29,33B | 39,64B | 33,75B |
| Cash & Equivalents | 19,71B | 24,11B | 21,86B | 12,89B | 14,49B |
| Current Assets | 55,62B | 55,89B | 53,50B | 55,29B | 60,98B |
| Current Liabilities | 54,13B | 50,32B | 46,28B | 55,80B | 45,23B |